"label","id","instanceType","description","name","uuid:ID","rationale"
"","StudyDesign_1","StudyDesign","The main design for the study","Study Design 1","1203ff9f-6cb7-4f17-af60-54c2b576529f","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
